This research area will focus on and extend the current state-of-the art knowledge on optimization of broad-spectrum antivirals, metagenomics-based diagnostics and the impact of specific vaccine design on the elicited immune response. These questions will be validated through in vivo and ex vivo experimental systems, heavily leveraging the unique access to unique clinical and vaccine cohorts and specimens in this consortium.